Drug Profile
Research programme: inflammatory bowel disease - Androclus Therapeutics
Alternative Names: AT-005; AT-007Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Androclus Therapeutics
- Class Peptides
- Mechanism of Action Immunomodulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Crohn's disease; Ulcerative colitis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Crohn's-disease in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Ulcerative-colitis in USA (PO)
- 20 Sep 2006 This programme is still in active development